The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

  ()
Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Products for Human Use also adopted a positive opinion for Dupixent in a third indication. read more >
News Update

Biopharma Reports Positive Data from Alcoholic Hepatitis Study

News Update
  ()
These results are from the recently completed clinical trial of the firm's lead drug candidate. read more >

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor

Research Report
  ()
The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. read more >

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News

  ()
Shares of migraine treatment research firm Alder BioPharmaceuticals soared 84% after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. read more >

Fibrocell Science Shares Rise 60% on Acquisition News

  ()
Fibrocell Science's shares traded up 60% after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share. read more >

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

  ()
Shares of Moderna Inc. traded up double-digits as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. read more >
News Update

Company Develops Cannabinoid-Measuring Process for Liquids

News Update
  ()
This proprietary method ensures the firm meets the requirements for its cannabis-containing beverages and oils. read more >

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

  ()
Lexicon Pharmaceuticals shares traded higher by more than 30% after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. read more >

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan

Research Report
  ()
The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report. read more >

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%

  ()
This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million. read more >

Mallinckrodt Shares Up 60% as It Announces Sale of Unit

  ()
Shares of Mallinckrodt Plc traded more than 60% higher on news that the company is selling its CDMO subsidiary BioVectra Inc. to H.I.G. Capital for $250 million. read more >

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results

  ()
Shares of ACADIA Pharmaceuticals opened up 75% higher after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. read more >
News Update

Technology License Triggers $10 Million Milestone Payment for Biopharma

News Update
  ()
This is the first of many such potential payments under the related agreement. read more >

Neon Therapeutics Shares Are Flashing Brightly after Reporting Predictive Cancer Breakthrough

  ()
After announcing publication in the scientific journal Immunity that it had created a 61-fold improvement process for predicting cancer-specific antigens, Neon Therapeutics' stock has traded wildly, up more than 46% at times on nearly 100-times average daily volume, but has since pulled back greatly. read more >

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

  ()
Shares of Global Blood Therapeutics traded more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. read more >

Coverage Initiated on 'Biotech Machine'

Research Report
  ()
The compelling reasons behind those descriptors are explored in a Dawson James Securities report. read more >

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

Research Report
  ()
The study data and their implications are provided in a BTIG report. read more >

Ardelyx's Shares Soar 65% as Tenapanor Phase 3 Study Hits the Mark

  ()
Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases. read more >

Lannett Signs Exclusive U.S. Distribution Deal with Sinotherapeutics; Shares Up 40%

  ()
Shares of Lannett Co. are up 40% today after announcing that it secured rights to be the exclusive U.S. distributor of Sinotherapeutics' antifungal drug that is an AB-rated generic for Noxafil. read more >

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

Research Report
  ()
The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. read more >

After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'

Research Report
  ()
Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. read more >

Why Provention Bio Is in My Portfolio

Contributed Opinion
  ()
Orphan drug and breakthrough therapy status, which could mean this company's lead candidate is on the FDA fast track, translates to huge opportunities for both those suffering from diabetes and investors, says Daniel Carlson of Tailwinds Research. read more >

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study

  ()
Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. read more >

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

Research Report
  ()
The next steps for each of the programs are outlined in a Dawson James Securities report. read more >

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

  ()
Solid Biosciences' shares are up by more than 40% after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. read more >
Showing Results: 1 to 25 of 103 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"DRRX earned a $10M milestone payment from Gilead."
– Ed Arce, H.C. Wainwright & Co.